Dapagliflozin and empagliflozin cut mortality from heart failure with reduced ejection fraction whether or not patients have ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

The following is a summary of “Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients ...

Diabetic retinopathy (DR) affects about 26 percent of people with diabetes. While many patients have an early form of DR, the condition can progress, posing the threat of irreversible vision loss.

Initiating empagliflozin vs a DPP-4 inhibitor may slow the progression of diabetic retinopathy in patients with type 2 ...

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.

Heart attacks are a leading cause of death and disability in Europe, and their effects often extend beyond the initial event, leading to chronic heart failure.

心力衰竭（HF）和心房颤动（AF）通常并存，二者关系密切，每一种疾病都会导致另一种疾病的发病率和患病率增加，并导致疾病预后恶化。两者并存给临床管理带来了诸多挑战。在2024年11月16日至18日盛大举行的2024年美国心脏协会科学年会（2024 ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

According to a report by the Public Health Foundation of India, 25% of people with diabetes in India have a high risk of ...